Patent Holder: University of Chile

Date: August 2023

In August 2023, under the auspices of WHO’s COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool signed a worldwide licence with the University of Chile for its technology designed as a system for quantification of neutralizing antibodies against SARS-CoV-2. This technology can be used in the facility using heightened control measures similar to biosafety level 2 laboratories.

MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for this technology by submitting an e-mail to CTAPDiagnostics@medicinespatentpool.org providing as much detail as possible as to what the developer intends to do with a sublicence.

Key Features
Aim of the Licence To facilitate the worldwide use of technology which allows to detect the presence of neutralising antibodies against SARS-CoV-2.
Products Any product that uses the licensed know-how or material.
Know‐how The University will provide all necessary know-how and materials to the licensees, specified in the licence
Field of use COVID-19
Territory Worldwide. The sublicensee shall not be a commercial entity either incorporated or manufacturing the products in Chile.
Scope of the grant Non-exclusive right to grant sublicences to develop the licensed know how/material into products, and to commercialize licensed products.
Royalties
  • royalty-free for low and middle-income countries.
  • 3% for high-income countries where the sublicensee has used the licensed technology for the manufacture of the products.
Term 10 years from the Effective Date
Announcement
Board resolution
Advisory Group Report
Country List